Apoptosis plays a central role in the regulation of normal tissue homeostasis and participates in the elimination of potentially dangerous cells including the precursors of tumor cells. Most currently used antitumor agents kill cancer cells by stimulating the apoptotic machinery, and therapy resistance can be attributed, at least in part, to a disabled apoptotic program. Apoptotic cell death and withdrawals from the cell cycle are tightly coordinated processes. In fact, mechanisms essential for regulation of the cell cycle also influence processes of cell death. 1 An important mechanism for cell cycle control involves inhibition of cyclin-dependent kinases (CDKs) by CDK inhibitors (CKIs). p57
Kip2 together with p21
Cip1 and p27 Kip1 belongs to the Cip/Kip family of CKIs, which plays a critical role in regulating cell proliferation. 2, 3 Importantly, only p57
Kip2 has been shown to play essential roles during embryogenesis that other cell cycle inhibitors cannot compensate for. p57 Kip2 -null mutant mice display severe developmental defects. [4] [5] [6] [7] Interestingly, many of the defects described are not directly linked to increased cell proliferation. 4, 5, 7 In addition, p57 Kip2 has been shown to influence cell differentiation of several cell types, implying that p57
Kip2 may have a broader scope of cellular action than only being a cell cycle inhibitor. [5] [6] [7] We and others have shown that p57 Kip2 -deficient mice exhibit an increase in the rate of cell death in several cell populations during embryogenesis. 4, 6, 7 Whether this increased apoptosis is a direct or indirect effect due to aberrations in cell proliferation and differentiation is not known. Importantly, the p57 Kip2 gene, located on chromosome 11p15.5, has been suggested to be a tumor suppressor gene, being inactivated in various types of human cancers. [8] [9] [10] [11] [12] However, little is known concerning p57 Kip2 function during apoptotic cell death during adulthood and its possible implication for cancer.
In the present study, we show that specific p57
Kip2 expression in HeLa cells sensitizes these cells to apoptosis induced by staurosporine (STS). Our studies reveal that p57 Kip2 primarily promotes the mitochondrial apoptotic pathway, favoring loss of mitochondrial transmembrane potential (DCm), and consequent release of cytochrome-c (cyt-c) into cytosol, caspase-9 and caspase-3 activation. Inhibition of p57
Kip2 proapoptotic function by Bcl2 overexpression or by the voltage-dependent anion channel (VDAC) inhibitor, 4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid (DIDS), further confirmed the requirement for the cyt-c/caspase-dependent mitochondrial cell death pathway downstream of p57 Kip2 . Thus, these results indicate that p57
Kip2 plays a critical role in regulation of the mitochondrial apoptotic cell death pathway in cancer cells.
Results
Staurosporine-induced apoptosis is strengthened by p57 Kip2 . To explore a putative role for p57 Kip2 during apoptosis, we took advantage of HeLa Tet-On-derived cell lines stably transfected with the tetracycline-inducible p57 Kip2 . 13 HeLa-p57 cells can be induced to selectively express p57
Kip2 upon administration of doxycycline (Dox) (Figure 1a ). HeLa-ctrl cells are control cells in which no increase in p57
Kip2 expression level occurs following Dox treatment. To investigate the effect of selective p57 Kip2 expression on STS-induced apoptosis, HeLa Tet-On cell lines were pretreated for 24 h with Dox (2 mg/ml), after which STS (0.1 mM) was added. Cells were harvested 5 h after STS addition and analyzed for apoptosis (Figure 1b) . Apoptotic nuclei were observed in both cell lines after STS treatment. Interestingly in HeLa-p57 cells, whereas the induction of p57
Kip2 expression did not provoke cell death, its induction before the addition of STS further increased the fraction of apoptotic cells. In contrast, Dox treatment of HeLa-ctrl cells had no apoptosis promoting effect.
A main issue is whether the observed death promoting effect of p57
Kip2 could be an overexpression artifact. In order to rule out that possibility, HeLa Tet-On cell lines were treated with Dox for 48 and 72 h, and apoptosis was assessed. Importantly, none of these cell lines upon Dox treatment exhibited more than 2% apoptotic cells up to 72 h (Figure 1c) . The sensitization to STS-killing effect by p57
Kip2 in HeLa-p57 cells was confirmed by fluorescence-activated cell sorting (FACS) analysis (Figure 1d) . One of the biochemical hallmarks of apoptosis is cleavage of poly(ADP-ribose)polymerase (PARP) induced by caspase-3. Appearance of the PARP cleavage product was observed in STS-treated HeLa-p57 cells. Processing of PARP correlated with caspase-3 activation (Figures 1e and 5a) . Nevertheless, total disappearance of native PARP was only observed in cells treated by Dox and then STS. These cells also exhibited an increased active caspase-3 level as compared to cells treated only with STS. Altogether, these results show that selective p57
Kip2 expression supports STS-induced apoptosis in HeLa cells. To notice, p57
Kip2 expression also sensitized HeLa cells to apoptosis induced by DNA damaging agents such as etoposide (VP16) and cisplatin (CP), but was ineffective in promoting death receptor-mediated apoptosis stimulated with agonistic antiFas antibodies (aFas) (Figure 2a ). In addition, p57 Kip2 proapoptotic effects were also observed in neuroblastoma SH-SY5Y cells (Figure 2b ) and ovarian carcinoma SKOV3 cells (Figure 2c) . However, the death promoting effect of p57 Kip2 was not seen in human embryonic kidney HEK-293 cells (Figure 2d ), suggesting some degree of cell type specificity.
Depletion of p57
Kip2 inhibits staurosporine-induced apoptosis. To further characterize and reveal the function of p57
Kip2 in apoptosis without the use of induced expression, we performed additional experiments using mouse embryo fibroblasts (MEF) derived from wild-type and p57
Kip2-/-mice. Importantly, STS-and VP16-induced apoptosis were considerably reduced in MEF cells derived from p57
Kip2-/-mice (Figure 3a and b) . These data provide evidence that p57
Kip2 is of importance for efficiency of the death program elicited by apoptotic stimuli such as STS and VP16. Kip2 promotes staurosporine-induced apoptosis by means of a CDK-independent mechanism. No major cell cycle perturbations were observed in p57
Kip2 expressing cells before the manifestation of apoptosis (Figure 4a) . 13 To further investigate if p57
Kip2 death promoting effects also depend upon the same domain as the antiproliferative ones, we used a mutated derivative of p57 Kip2 (p57CDK mut ) that is unable to inhibit CDK activity. 7, 14 p57CDK mut , which contains two substitutions in the cyclin binding domain and two in the CDK binding region, has lost its capability to physically interact with CDK2 and therefore its ability to inhibit its activity (Figure 4b and c).
14 Although p57CDK mut is unable to induce cell cycle arrest, it retains the ability to promote STS-induced apoptosis (Figure 4d ). Taken together, these data provide compelling evidence indicating that p57
Kip2 promotes cell death by a mechanism that is independent of its ability to inhibit CDK activity.
p57
Kip2 supports staurosporine-induced caspase-3 and caspase-9 activities. STS-induced cell death was inhibited by the caspases' inhibitor zVAD-fmk, indicating that STSinduced cell death is mediated by caspases activation (Figure 5e ). To confirm caspases' activation in STS-treated HeLa cells and to evaluate the consequence of p57 Kip2 expression, cleavage of specific fluorogenic substrates, which correspond to preferred cleavage site for caspase-3 like (Figure 5a ), caspase-2 (Figure 5b ), caspase-8 ( Figure 5c ) and caspase-9 enzyme (Figure 5d ) was monitored. Caspase-2 and caspase-3 activities were detected already after 2 h STS treatment. We were not able to notice significant increase in caspase-8 and caspase-9 activities upon STS treatment alone. Interestingly, HeLap57 cells pretreated with Dox exhibited an increase in caspase-3 and caspase-9 activities already at 2 h after STS treatment, whereas significant effects on caspase-2 and caspase-8 were only detectable at 5 h post STS treatment. In order to further characterize which caspases are mediating the p57
Kip2 cell death promoting effect, p57 Kip2 expressing cells were pretreated with DEVD-fmk (caspase-3 inhibitor), LEHD-fmk (caspase-9 inhibitor) or VDVAD-fmk (caspase-2 inhibitor) before addition of STS. Each of these inhibitors leads to a reduction of STS-killing effect, implying that caspase-2, caspase-3 and caspase-9 activities account for STS-induced cell death (Figure 5e ). However, whereas p57
Kip2 was still able to promote STS-induced apoptosis in the presence of caspase-2 inhibitor, caspase-3 and Kip2 inhibits STS-and VP16-induced apoptoses. MEF cells derived from wild-type and p57
Kip2-/-mice were treated with 0.1 mM STS for 5 h (a) or 2 mg/ml VP16 for 24 h (b). Cells were fixed and nuclei were stained with Hoechst 33342. Apoptosis was assayed by scoring cells presenting condensed or fragmented nuclei. Three hundred nuclei were analyzed in duplicate and each experiment was repeated three times. Data are represented as mean7S.E.M. Kip2 promotes apoptotic cell death P Vlachos et al caspase-9 inhibitors abrogated p57 Kip2 proapoptotic effects. Thus, whereas STS treatment leads to the activation of several caspases, p57
Kip2 only supported caspase-9 and caspase-3 activities, suggesting that p57
Kip2 acts upstream of their activation.
Kip2 promotes and accelerates staurosporineinduced mitochondrial dysfunctions. Mitochondria play an important role in the regulation of apoptosis. Specifically, the release of several proteins, including cyt-c and apoptosis inducing factor (AIF), normally located in the intermembrane space of mitochondria, has been observed during the early stages of apoptotic cell death. 15 We therefore decide to examine if the mitochondrial cyt-c/caspase-9-activated pathway could be a target for the p57 , HA-p57CDK mut , CDK2 or their combinations for 24 h. Total cell extracts from transfected cells were subjected to immunoblotting with anti-p57
Kip2 or anti-Cdk2 antibodies (inputs, top panels). Total cell extracts were immunoprecipitated by using anti-HA antibody and immune complexes were subjected to immunoblotting by using anti-p57
Kip2 or anti-Cdk2 antibodies (IP, lower panels). (c) HeLa cells were transfected with expression vectors encoding HA-p57
Kip2 or HA-p57CDK mut for 24 h. Total cell extracts were immunoprecipitated by using anti-CDK2 antibody and kinase activity in the CDK2 complexes was measured by the incorporation of [g-32 P]ATP into Histone H1. Data are presented as the fold increase over basal levels. Each experiment was repeated three times. (d) HeLa cells were transfected with expression vectors encoding p57 Kip2 or p57CDK mut for 24 h and then treated with STS for 5 h. Cells were then processed for immunofluorescence using antip57
Kip2 antibody. Nuclei were counterstained with Hoechst 33342 and apoptosis was assayed as described in Figure 2b Kip2 promotes apoptotic cell death P Vlachos et al cells consistently failed to show difference in the kinetic of DCm loss upon STS treatment as compared to control cells (data not shown). In contrary, GFP-p57 expressing HeLa cells lost their DCm faster than the non-expressing ones (Figure 6d and Supplementary Movie S1). In fact, 147 min after STS treatment, 50% of the p57
Kip2 expressing cells were TMRE negative, whereas it took 209 min to obtain the same effect in control cells (Figure 6c) . Altogether, these data demonstrated that p57
Kip2 not only enhances but also accelerates STS-induced mitochondrial apoptotic events and suggest that mitochondrial disruptions are corner stone for p57
Kip2 proapoptotic effects. nuclear staining was observed already after 2 h STS treatment. However, using this method, we were unable to detect cytoplasmic localization for p57 Kip2 (data not shown). We took advantage of GFP tag, which allows tracing of protein in live cells. We used time-lapse confocal microscopy imaging of HeLa cells expressing GFP-p57 to visualize changes in the localization of p57
Kip2 during STS-induced apoptosis. In order to follow p57
Kip2 subcellular localization, cells were cotransfected with DsRed-mito to label the mitochondria and the nuclei were labeled with Hoechst 33342. Within about 20 min after STS exposure, a GFP-p57 punctuate cytoplasmic staining pattern with some preference for the perinuclear area was yielded (Figure 7a ). The mitochondrial subcellular preference was confirmed by the fluorescence overlapping between GFP-p57 and DsRed-mito Kip2 promotes apoptotic cell death P Vlachos et al (Figure 7b ). The p57 Kip2 protein contains a nuclear localization signal (NLS).
2 Therefore, as control, NLS-GFP expressing HeLa cells were challenged with STS and changes in GFP fluorescence were visualized by live confocal fluorescence imaging. Up to 2 h after treatment, GFP fluorescence was restricted to the nuclei compartment, demonstrating that the translocation of GFP-p57 to the mitochondria upon STS apoptotic stimulus was specific (Figure 7c ).
Mitochondrial outer-membrane permeabilization, which regulates the release of apoptosis promoting proteins, from the mitochondrial intermembrane space, is controlled by proand antiapoptotic members of the Bcl2 family. The antiapoptotic family members Bcl2 and BclxL have been shown to block release of apoptosis promoting proteins, whereas proapoptotic members such as Bax promote the same. 16 Therefore, based on the observed relocalization of p57
Kip2 to the mitochondria upon STS exposure, we decided to explore Kip2 promotes apoptotic cell death P Vlachos et al the effect of p57 Kip2 on Bax activation. Bax activation was investigated in HeLa-p57 cells by confocal immunofluorescence microscopy using antibodies against the active form of this protein. 16, 17 HeLa-p57 cells after Dox addition displayed identical features to control cells for this parameter. In contrast, pretreatment with Dox markedly increased STSinduced Bax activation and relocalization to the mitochondria (Figure 7d) .
Requirement of the mitochondrial apoptotic pathways for p57
Kip2 proapoptotic effects. A change of mitochondrial membrane permeability is essential for apoptosis, leading to translocation of apoptogenic cyt-c and AIF into the cytoplasm. 18 The Bcl2 family of proteins regulate DCm and release of mitochondrial proteins by directly modulating the activity of VDAC through binding. 19 Whereas, Bax alters the physical properties of the VDAC, making the VDAC permeable to cyt-c, Bcl2, through its BH4 domain, maintains VDAC in a closed configuration. 19 Since Bcl2 is thought to protect cells from apoptotic death by preventing the dissipation of DCm and subsequent cyt-c/AIF release, we investigated the ability of Bcl2 overexpression to block p57
Kip2 proapoptotic effects (Figure 8a ). For this purpose, HeLa and Bcl2 overexpressing HeLa cells (HeLa-Bcl2) were transfected with p57
Kip2 expression vector and then treated or not with STS for 5 h. STS-induced apoptosis was severely reduced in Bcl2 overexpressing cells, indicating that engagement of the mitochondrial-dependent apoptotic pathway account predominantly for STS-killing effect. In addition, whereas p57
Kip2 expression potentiated STSinduced apoptosis in HeLa cells, its expression had no effect in HeLa-Bcl2 cells. These results suggested that Bcl2 overexpression in HeLa cells inhibits p57
Kip2 positive effect on STS-induced apoptosis. To notice, Bcl2 overexpression in HeLa cells was also able to suppress p57
Kip2 promoting effect on VP16-and CP-induced cell death (data not shown). In order to validate that Bcl2 expression effectively prevented mitochondrial dysfunction, cyt-c and AIF release into the cytosol were investigated in both cell types (Figure 8b ). p57
Kip2 expression strengthened the release of these mitochondrial proteins into the cytosol in HeLa cells. On the other hand, in HeLa-Bcl2 cells, no cyt-c and AIF release were detected upon STS treatment alone or in combination with p57
Kip2 ectopic expression, demonstrating that Bcl2 indeed blocked the mitochondrial apoptotic pathway. We then examined the consequence of Bcl2 overexpression on caspase-3-like activity (Figure 8c ). Again, whereas p57 Kip2 promoted STS-induced DEVDase activity in HeLa cells, its expression had no effect in HeLa-Bcl2 cells. To notice, STS-induced caspase-3 activity in HeLa-Bcl2 cell line was extensively reduced as compared to HeLa cell line. This observation suggests that STS treatment leads to the Kip2 promotes apoptotic cell death P Vlachos et al activation of two caspases-dependent apoptotic pathways: one dependent on mitochondrial event, which can be inhibited by Bcl2 protein and promoted by p57 Kip2 and another independent of mitochondrial event, which can therefore not be blocked by Bcl2 or enhanced by p57
Kip2
Finally, to further confirm that mitochondria are the target of p57
Kip2 proapoptotic effect, and since Bcl2 has been shown to inhibit mitochondrial-dependent apoptosis by blocking VDAC, 19 the effect of DIDS, a chemical inhibitor of this mitochondrial porin, was tested (Figure 8d ). Results obtained with VDAC inhibition were similar to those obtained with Bcl2 overexpression, as DIDS treatment inhibited p57 Kip2 positive effect on STS-induced apoptosis. In summary, Bcl2 overexpression or VDAC inhibition resulted in repression of p57 Kip2 proapoptotic effect.
Discussion

Although p57
Kip2 -null mutant mice exhibit an increase in the rate of cell death in several cell populations during embryogenesis, [4] [5] [6] [7] whether this increased apoptosis is a direct or indirect effect due to aberrations in cell proliferation and differentiation is still discussed. For example, it seems that in the p57
Kip2 -deficient retina, apoptosis precisely compensates for the inappropriate proliferation to preserve the correct proportion of the major retinal cell types. 6 In contrast, p57
Kip2 promotes differentiation of dopaminergic neurons in vivo after they have already exited the cell cycle, and occurrence of cell death in the p57 Kip2 mutant ventral midbrain can probably be attributed to the deficient late maturation of dopamine cells. 7 Taken together, these observations suggest that that p57 Kip2 exerts tissue-specific effects during development.
Interestingly during adulthood, it has also been reported that p57
Kip2 expression is reduced in various tumors, [8] [9] [10] [11] [12] [20] [21] [22] [23] [24] suggesting a possible function for this protein in tumorigenesis. Importantly, decreased p57 Kip2 expression may provide an important prognostic implication for patients with ovarian, hepatocellular and colorectal cancers, and acute lymphoblastic leukemia. [8] [9] [10] 23 In spite of frequent low/absence of p57 Kip2 expression in various tumors, rare/no somatic mutations of p57 Kip2 gene are found in these tumors. [8] [9] [10] [11] [12] These observations suggest that inactivation of p57 Kip2 gene expression, rather than mutations in the p57 Kip2 gene, accounts for the involvement of p57
Kip2 in other types of cancer. Accordingly, inactivation of p57 Kip2 by regional promoter hypermethylation and histone deacetylation has been suggested in human tumors. 25, 26 Finally, several apoptotic stimuli, including treatment with hypomethylating agents, histone deacetylase inhibitors 27 or p73beta overexpression 28 have been shown to induce p57 Kip2 expression. In the case of p73beta-mediated apoptosis, silencing p57
Kip2 considerably reduced cell death, suggesting that p57
Kip2 was required. 28 Although p57 Kip2 has been suggested to be a tumor suppressor gene, being inactivated in various types of human cancers, its precise involvement in apoptosis in response to cytotoxic drugs or during tumorigenesis is unclear.
To further elucidate these issues, the effects of ectopic p57
Kip2 expression alone or in the presence of the cytotoxic drug STS on the apoptotic execution machinery were investigated. STS-induced mitochondrial disruption leads to the activation of the cyt-c/caspase-9/caspase-3 mitochondrial-dependent apoptotic pathway in HeLa cells. Experiments using the broad-spectrum inhibitor of caspases, zVADfmk, and the VDAC inhibitor, DIDS, or Bcl2 overexpression, also revealed that caspases are required for STS-induced apoptosis in HeLa cells, and that mitochondrial dysfunctions such as loss of DCm and cyt-c release account mostly for the STS-killing effect. Our results suggest that the CKI p57 Kip2 bears proapoptotic properties, which are independent of its ability to inhibit CDK activity. p57
Kip2 proapoptotic effects were observed in several cell types (HeLa, SH-SY5Y, SKOV3 and MEF). However, these effects could be cell type specific. In fact, it has previously been reported that p57
Kip2 expression inhibits green tea polyphenol-induced apoptosis in oral carcinoma cells 29 or suppresses UV-and MEKK1-induced apoptotic cell death in HEK-293 cells. 30 However, to our surprise, in our hands, p57
Kip2 expression did not prevent UV-, STS-and CP-induced apoptotic cell death in HEK-293 cells. The cell type-specific effect may be related to differences in the stability of p57
Kip2 within cells or the number of cell survival pathways that are active in a particular cell type.
As apoptosis is a cell type-specific process, the ability to resist p57
Kip2 death promoting effect may, at least, be partially, attributed to cell-and tissue-specific differences in the function of apoptotic and antiapoptotic signal transduction pathways. The abundance of p57
Kip2 is thought to be controlled by the ubiquitin-proteasome pathway. Phosphorylation at threonine residue (Thr-310) of human p57
Kip2 is required for Skp2-mediated ubiquitylation and proteolysis. 31 Therefore, potential differences in p57
Kip2 post-translational modifications could in principle also influence its function in a cell type-specific manner. To notice, cell type specificity effects on apoptosis have also been reported for another member of the Cip/Kip family, p27 Kip1 . Indeed, overexpression of this CKI has been shown not only to protect HeLa cells from STS-induced apoptosis but also to induce apoptosis in several transformed mammalian cell lines. 32 Furthermore, it comes into view that p57
Kip2 exerts its proapoptotic effect on the mitochondrial-dependent apoptotic pathways and has no direct effect on the mitochondrialindependent ones. The conclusion that p57
Kip2 sensitizes cells to mitochondrial-dependent stimulus of apoptosis is supported by several observations. First, p57
Kip2 expression improved STS-induced cyt-c release into the cytosol. In addition, whereas STS caused the activation of several caspases, p57
Kip2 expression only supported at early time point caspase-9 and caspase-3 like activities. These data suggest an improvement of the mitochondrial cyt-c/caspase-9/caspase-3-activated apoptotic pathway in p57
Kip2 expressing cells. Second, p57
Kip2 expression not only increased the fraction of cells presenting a low DCm after STS treatment but also accelerated this mitochondrial apoptotic event, as p57 Kip2 expressing cells lose their DCm faster than the non-expressing ones. Third, translocation of p57
Kip2 from the nucleus to the mitochondria was detected in live HeLa cells within 20 min after STS exposure. In fact, cytoplasmic localization for p57 Kip2 has been reported in non-small-cell lung carcinoma 20 and esophageal squamous cell carcinoma. 33 In addition, during osteoblast differentiation, cytoplasmic p57
Kip2 was found to inhibit LIM-kinase 1, a kinase involved in actin p57
Kip2 promotes apoptotic cell death P Vlachos et al filament dynamics, by translocating and sequestering it in the nucleus. 34, 35 Possible cytoplasmic functions for the other Cip/ Kip CKIs have also been described. 32, 34 For example, p21
Cip1 and p27 Kip1 also appear to be implicated in actin dynamics, at least partially, through regulation of the RhoA pathway. 32 Another important role for cytoplasmic p21
Cip1 in the protection of cells against apoptosis has been proposed. 34 p21
Cip1 can relocate to the mitochondria, where it interacts with procaspase-3 to inhibit caspase 3 activation and to resist Fas death receptor-induced cell death. 32, 36 Finally, p57 Kip2 expression appears to facilitate Bax activation and translocation to the mitochondria upon STS treatment. Whether the translocation of p57
Kip2 to the mitochondria is directly related to the activation of Bax activation still awaits additional experiments. However, in agreement, Bcl2 overexpression, which is thought to protect cells from apoptotic death by preventing the dissipation of DCm and subsequent cyt-c/AIF release, totally abrogated p57
Kip2 proapoptotic property. Since Bcl2 has been shown to prevent mitochondrial-dependent apoptosis by blocking VDAC, 19 the effect of VDAC inhibition by DIDS was looked at. DIDS treatment inhibited p57
Kip2 positive effect on STSinduced apoptosis in HeLa cells. Altogether, these results demonstrated that the presence of p57
Kip2 sensitizes cells to apoptotic stimuli involving mitochondrial pathways.
The cytotoxic effects of many anticancer drugs are mediated via the apoptotic pathways. Chemoresistant tumor cells have acquired the ability to evade the action of multiple classes of anticancer drugs. Mitochondrial membrane permeabilization is a critical event in the process leading to physiologic or chemotherapy-induced apoptosis. 37 Since mitochondria are critical 'gatekeepers' to the apoptosis process, uncovering their biological regulators and better understanding of mitochondrial cell death pathways may provide insights into sensitivity or resistance of tumor cells. Moreover, this knowledge could be further exploited to restore efficient apoptotic pathways in order to increase sensitivity of tumor cells to therapy. Cell culture, transfection and treatments. Cervical carcinoma HeLa, HeLa-Bcl2, ovarian carcinoma SKOV3, neuroblastoma SH-SY5Y and human embryonic kidney HEK-293 cells were cultured and transfected as described. 7, 38 MEF cells derived from wild-type and p57
Kip2À/À mice (gifts from CL Stewart, National Cancer Institute) were maintained in DMEM supplemented with 10% FCS, 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml). The cell line derived from HeLa cells in which p57
Kip2 expression is under control of tetracycline, HeLa-p57, and HeLa-ctrl, used as negative control, have been previously described (gifts from S Okret, Karolinska Institute). A 2 mg/ml volume of Dox was added to the culture medium to induce expression of p57
Kip2 in Tet-On cell line. HeLa-Bcl2, a stable, Bcl2 expressing cell line derived from HeLa cells transfected with a Bcl2 expression plasmid, has been described previously (gift from DJ McConkey, MD Anderson Cancer Center). Transfections were performed with LipofectAMINE PLUS according to the manufacturer's protocol. As control, cells were transfected with an empty vector. Twenty-four hours after transfection, cells were treated with 0.1 mM STS (Sigma), 20 mg/ml etoposide (VP16, Bristol-Meyers), 10-20 mM CP (Bristol-Meyers) or 200 ng/ml agonistic anti-Fas Abs clone CH-11 (aFas, Medical & Biological Laboratories Ltd.) for the indicated time period. For time-lapse experiments and cytosol extract preparation, cells were treated with 0.2 mM STS. Caspase inhibitors zVAD-fmk, DEVD-fmk, LEHD-fmk and VDVAD-fmk, used at 10 mM, were purchased from Enzyme Systems Products and added 1 h before STS treatment. The VDAC blocker, DIDS, used at 300 mM, was obtained from Sigma. The cell density was maintained at levels allowing exponential growth.
Detection of apoptosis. After treatment, cells were fixed in 4% paraformaldehyde and subsequently DNA was stained with Hoechst 33342 (0.1 mg/ml, Molecular Probes). The number of apoptotic cells was measured quantitatively by assessing the percentage of cells with fragmented or condensed nuclei.
Measurement of caspase activity. The measurement of DEVD-AMC, VDVAD-AMC, IETD-AMC or LEHD-AMC (Peptide Institute Inc.) cleavage was performed in a standard reaction buffer using a modified version of a fluorometric assay reported previously. 38 Cleavage of the fluorogenic peptide substrates was monitored by AMC liberation in a Fluoroscan II plate reader (Labsystems) using 355 nm excitation and 460 nm emission wavelengths.
Assessment of mitochondrial depolarization. For detection of mitochondrial membrane potential change, harvested cells were stained by TMRE, a lipophilic, cationic fluorochrome dye that is only taken up by mitochondria having an intact electrochemical gradient (Molecular Probes), for 30 min at 371C and then analyzed by flow cytometry on a FACSCalibur flow cytometer equipped with CellQuest software (Becton Dickinson).
Subcellular fractionation, immunoprecipitation and Western blot analysis. Total, cytoplasmic and nuclear protein extracts were prepared as reported. 7 For immunoprecipitation, protein Sepharose-precleared total protein extracts were incubated with the indicated antibody in nuclear extract buffer for overnight at 41C. Immunocomplexes bound to protein A-Sepharose or protein G-Sepharose were collected by centrifugation and washed in radioimmunoprecipitation assay (RIPA) buffer. For immunoblot analysis, cell extracts were resolved on SDS-PAGE and blotted; protein fragments were detected with anti-AIF, anti-p57 Kip2 C20 (Santa Cruz Biotechnology), anti-cleaved caspase-3 (Cell Signaling), anti-PARP or anti-cyt-c (BD Pharmingen) antibody. Immunoblot with anti-glyceraldehyde-3-phosphate dehydrogenase (anti-G3PDH) antibody (Trevigen) was used for standardization of protein loading. Bands were visualized by enhanced chemiluminescence (ECL Plus) following the manufacturer's instructions (Amersham).
CDK activity assay. For CDK2 kinase assay, cell lysates (500 mg) were immunoprecipitated with anti-CDK2 M2 antibody (Santa Cruz Biotechnology). The immunoprecipitate was incubated with histone H1 (CDK kinase assay kit; Upstate Biotechnology) in the presence of p32-labeled g-ATP for 10 min at 301C The reaction products were separated by SDS-PAGE and phosphorylated histone H1 proteins were detected by autoradiography and quantified by ImageJ software.
Cell cycle distribution analysis by flow cytometry. The distribution of cells in the G1, S and G2/M cell cycle phases was determined by DNA flow cytometry as described earlier. 38 Cells were harvested and fixed with ice-cold 70% ethanol for 1 h. Samples were then washed with PBS and stained with propidium iodide (PI) in presence of RNase A. FACS analysis was carried out using on a FACSCalibur.
Immunofluorescence, confocal microscopy and time-lapse recording. Anti-p57
Kip2 C20 and anti-active Bax N20 antibodies (Santa Cruz Biotechnology) were used for immunodetection. Alexa Fluor 488-conjugated antiIgG was used as secondary antibody (Molecular Probes). Paraformaldehyde-fixed cells and sections were blocked in Hepes/3%BSA/0.3%triton and successively incubated with primary (41C, 16 h) and secondary antibodies (room temperature, 1 h). Cell nuclei were counterstained with 1 mg/ml Hoechst 33342. Mounting was performed with VECTASHIELD (Vector Laboratories). Kip2 promotes apoptotic cell death P Vlachos et al
